Ceapro Inc V.CZO

Revenues

[Alex1726]

When you compare the last 2 quaters of 2022 versus 2021 revenues are down 11.35%. Last year the first quater was $6 172M , for the share price to regain value they must come up with a very strong Q1 otherwise the stock will collapse. It is very likely the revenues has stalled. Also Gagnon realised or someone made him realised he can't afford to move on every front (PGX , AV PILL AND FIBROSIS)

Even Gagnon's parrot (proph) would never buy any shares even at the current level , i am pretty sure he does not own one single share.

[Ciao]

IMHO rev came in as forecasted but the loss was somewhat unexpected. As for the reasons pushing back the target date for the commercial PGX scale up (though some have speculated a hold) we do not have an official answer. Funds are on hand ($14M) to fund the AV trial, PGX install and would be able to cover the Y-BG study if it was a go. As for revenues this year, that remains a mystery, do we

[prophetoffactz]

"We know that sales growth for the year was in the range of the "8 - 10%""  No need for a range. Sales growth has been reported and was 9.56%.    

[boazklinghorn]

Seems obvious that until we have an offtake agreement or at least very clear line of site to an offtake agreement for the production from this expanded plant there is really no point in spending the money to build it. Maybe Sigrun can get us a deal, if she even actually exists. 

[Ciao]

That could provide clarity and confidence that the plant would go ahead. They said it would be a go ahead as they would  pursue Y-BG alone as an immune booster. The selection of a partner for PGX CoQ10 was to be announced in H2. Both require a commercial pilot plant. We still don't know the reason for the delay for completion, an explanation was lacking in the NR. The uncertainty adds to

[prophetoffactz]

"We still don't know the reason for the delay for completion, an explanation was lacking in the NR." The most immediate possibility that suggests itself is that having licensed the faciity at the University of Alberta and with five months 'boots on the ground' it is now clearer what has to be done. CZO is in a position to no longer talk just theoretically but with its arms

[Ciao]

We only know that the plant in Europe (Germany?) did not go ahead else it would have been completed by now. After doing "due diligence" with boots to the ground in their backyard they selected the AFPD facility which had the infrastruture and where Dr. Temelii set up PGX. So a 12 month timeline which was set out has been stretched out now to 18 months with no explanation. 

[prophetoffactz]

"We only know that the plant in Europe (Germany?) did not go ahead else it would have been completed by now." CZO had ideally wanted a 40 million dose per year plant with a $100 million NPV. It wanted to list on NASDAQ and do a financing at one point. In Feb. 2021 the biotech market began the worst bear market in history. There were also COVID delays and ongoing shutdowns and

[boazklinghorn]

CZO doesnt have the money or the marketing reach to bring a YBG product to market alone. If anyone doubts that I would refer you to the marketing team at Juvente. Both YBG and Q10 need a strong partner to succeed. At this stage PGX validation by a strong partner,leading to a successful product launch is more important than Gilles idea that he can somehow do this alone with no marketing team and no

[prophetoffactz]

boazklinghorn, "At this stage PGX validation by a strong partner,leading to a successful product launch is more important than Gilles idea that he can somehow do this alone with no marketing team and no budget."   "This next phase of scale up will allow us to work with commercial partners in nutraceuticals and pharmaceuticals to formulate, test, and commercialize novel products

[boazklinghorn]

Damn Proph do we agree?  That finally signing a real deal for real money with a real company is the only way forward and the only way for Gilles to keep his job. I knew you'd come around eventually.  

[Hopeforthebest]

In this last string of comments on Czo's dismal performance in Q3&Q4 there is one common denomitor by all contributors, the lack of communication by gagnon and his desire to keep the shareholders in the dark on critical information. Unfortunately this is not a new development with gagnon and is the primary reason the stock went from a darling of the TSXv to the armpit with maybe 5 trades